tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MEI Pharma Welcomes New Board Member Joshua Riezman

Story Highlights
MEI Pharma Welcomes New Board Member Joshua Riezman

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from MEI Pharma ( (MEIP) ) is now available.

On August 5, 2025, Steven D. Wood resigned from the board of directors of MEI Pharma, Inc., with no disagreements regarding the company’s operations or policies. On the same day, Joshua Riezman, Managing Director at GSR Strategies, LLC, was elected to the board, reflecting a strategic alignment with GSR, a crypto market making and trading firm, which has an Asset Management Agreement with MEI Pharma.

Spark’s Take on MEIP Stock

According to Spark, TipRanks’ AI Analyst, MEIP is a Neutral.

MEI Pharma’s overall stock score is low, primarily due to significant financial performance challenges and poor valuation metrics. Weak revenue and profitability, declining asset base, and negative cash flow contribute to a fragile financial position. Additionally, technical indicators suggest a bearish trend, further impacting investor sentiment. Without clear guidance or positive corporate events, the stock’s outlook remains unfavorable.

To see Spark’s full report on MEIP stock, click here.

More about MEI Pharma

Average Trading Volume: 1,005,470

Technical Sentiment Signal: Buy

Current Market Cap: $33.65M

See more data about MEIP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1